With understandable fanfare, SurModics recently announced a deal with Roche and Genentech for the delivery of injected Lucentis – an antibody treatment for wet age-related macular degeneration (AMD) with $2 billion in annual...
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)